Published: Jan 07, 2021
WALTHAM, Mass. (BUSINESS WIRE) TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the appointment of Brian M. Silver, J.D., to its Board of Directors. Mr. Silver is Chief Financial Officer and Head of Corporate Development at Freeline Therapeutics Holdings plc, a clinical-stage systemic gene therapy company.
Prior to joining Freeline in 2018, Mr. Silver was Partner and Head of Biotechnology in the healthcare practice at Perella Weinberg Partners, a leading independent global advisory firm. Prior to Perella Weinberg, Mr. Silver held a number of positions in Morgan Stanley’s healthcare investment banking group, most recently as Managing Director from 1998 to 2013. He began his career in the corporate transactions group at Sullivan & Cromwell. His advisory experience spans dozens of transactions, including mergers and acquisitions, joint ventures an
SHAREHOLDER ALERT: Rigrodsky & Long, P A Announces Investigation of FinTech Acquisition Corp IV Merger
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
SPACs Push it to the Limit into New Year s Eve
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
By Reuters Staff
2 Min Read
(Reuters) - Boutique investment bank Perella Weinberg Partners on Wednesday agreed to go public through a merger with a blank-check firm, or a special purpose acquisition company (SPAC), backed by banking entrepreneur Betsy Cohen in a deal valued at $975 million.
Cohen’s FinTech Acquisition Corporation IV, which had raised $230 million in September through an initial public offering (IPO), will acquire Perella Weinberg in a deal that includes a commitment of $125 million from investors such as Fidelity Management and Wellington Management.
The merged entity will list on the Nasdaq under the symbol ‘PWP’, the companies said in a statement. The deal is expected to close in the first half of 2021, pending approvals.